Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Alexandar Tzankov, Zijun Y. Xu-Monette, Marc Gerhard, Carlo Visco, Stephan Dirnhofer, Nora Gisin, Karen Dybkaer, Attilio Orazi, Govind Bhagat, Kristy L. Richards, Eric D. Hsi, William W L Choi, J. Han Van Krieken, Maurilio Ponzoni, Andrés J M Ferreri, Qing Ye, Jane N. Winter, John P. Farnen, Miguel A. Piris, Michael B. MøllerM. James You, Timothy Mcdonnell, L. Jeffrey Medeiros, Ken H. Young

Research output: Contribution to journalArticlepeer-review

Abstract

In order to address the debatable prognostic role of MYC rearrangements in diffuse large B-cell lymphoma patients treated with rituximab, cyclophosphamide, hydroxydaunorubicin, vincristine, and prednisone, we evaluated MYC rearrangements by fluorescence in situ hybridization in 563 cases using break-apart probes and IGH/MYC dual-fusion probes. Concurrent BCL2 and BCL6 aberrations were also assessed. Data were correlated with clinicopathological variables and prognostic parameters. MYC rearrangements were observed in 39/432 evaluable cases (9%), including 4 rearrangements detectable only with the dual-fusion probes, 15 detectable only with the break-apart probes and 20 detectable with both dual-fusion probes and break-apart probes. MYC rearrangements correlated with germinal center B-cell origin (P=0.02), MYC protein expression (P=0.032), and larger tumor mass size (P=0.0003). Patients with MYC rearrangements were more likely to be treatment resistant (P

Original languageEnglish
Pages (from-to)958-971
Number of pages14
JournalModern Pathology
Volume27
Issue number7
DOIs
Publication statusPublished - 2014

Keywords

  • diffuse large B-cell lymphoma
  • FISH
  • germinal center B-cell
  • MYC
  • prognosis
  • rearrangement
  • translocation

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Medicine(all)

Fingerprint Dive into the research topics of 'Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP'. Together they form a unique fingerprint.

Cite this